UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 257

Sortiert nach

Analysis of burden in caregivers of people with Alzheimer’s disease using self-report and supervision hours

The Journal of nutrition, health & aging, 2014-07, Vol.18 (7), p.677-684

2014

Volltextzugriff (PDF)

Inclusion Of Multiple Studies In Matching Adjusted Indirect Comparisons (Maic)

Value in health, 2015-05, Vol.18 (3), p.A33-A33

2015

Volltextzugriff (PDF)

Utilization of Observational Data as a Proxy Cohort for Comparison Purposes with Open-Label Study Results: An Example from Alzheimer’s Disease

The journal of prevention of Alzheimer's disease, 2019, Vol.6 (2), p.90-99

2019

Volltextzugriff (PDF)

Dependence Levels as Interim Clinical Milestones Along the Continuum of Alzheimer's Disease: 18-Month Results from the GERAS Observational Study

The journal of prevention of Alzheimer's disease, 2017, Vol.4 (2), p.72-80

2017

Volltextzugriff (PDF)

How to deal with missing longitudinal data in cost of illness models in alzheimer’s disease – suggestions from the geras study results

VALUE IN HEALTH, 2014, Vol.17 (3), p.A185-A185

2014

Volltextzugriff (PDF)

What Factors Predict the Decision to Treat Acute Coronary Syndrome Invasively? Evidence from Clinical Practice

Value in health, 2013-11, Vol.16 (7), p.A539-A539

2013

Volltextzugriff (PDF)

Analysis of factors that affect outcome of primary cadaveric renal transplantation in the UK

The Lancet (British edition), 1999-10, Vol.354 (9185), p.1147-1152

1999

Volltextzugriff (PDF)

Analysis of burden in caregivers of people with Alzheimer's disease using self-report and supervision hours

The Journal of nutrition, health & aging, 2014-07, Vol.18 (7), p.677-684

2014

Volltextzugriff (PDF)

Factors associated with long-term impact on informal caregivers during Alzheimer's disease dementia progression: 36-month results from GERAS

International psychogeriatrics, 2020-02, Vol.32 (2), p.267-277

2020

Volltextzugriff (PDF)

MSR56 Evaluating the Impact of Using Different Risk Equations for Cost-Effectiveness Evaluation in the US Setting

Value in health, 2022-07, Vol.25 (7), p.S529

2022

Volltextzugriff (PDF)

Determinants of societal costs in Alzheimer's disease: GERAS study baseline results

Alzheimer's & dementia, 2015-08, Vol.11 (8), p.933-945

2015

Volltextzugriff (PDF)

PCR59 Assessing the Utility Associated with Caregiving in Alzheimer's Disease (AD) with Mild Cognitive Impairment (MCI) and AD Dementia in Japan

Value in health, 2022-07, Vol.25 (7), p.S551-S552

2022

Volltextzugriff (PDF)

PCR24 The Impact of Informal Caregiving in Alzheimer’s Disease Dementia: A Health Utility Study in the UK

Value in health, 2022-07, Vol.25 (7), p.S545

2022

Volltextzugriff (PDF)

Health-related quality of life in people with predementia Alzheimer's disease, mild cognitive impairment or dementia measured with preference-based instruments: a systematic literature review

Alzheimer's research & therapy, 2020-11, Vol.12 (1), p.154-154, Article 154

2020

Volltextzugriff (PDF)

The GERAS Study: a prospective observational study of costs and resource use in community dwellers with Alzheimer's disease in three European countries--study design and baseline findings

Journal of Alzheimer's disease, 2013-01, Vol.36 (2), p.385

2013

Volltextzugriff (PDF)

CO19 Sintilimab Plus Chemotherapy for First-Line Treatment of Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer (AMNSQNSCLC): A Systematic Literature Review (SLR) and Network Meta-Analysis (NMA)

Value in health, 2022-07, Vol.25 (7), p.S307

2022

Volltextzugriff (PDF)

Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study

International journal of clinical practice (Esher), 2007-11, Vol.61 (11), p.1850-1862

2007

Volltextzugriff (PDF)

PCV9 Optimal Treatment Shortfalls and Worse 12-Month Outcomes for Diabetic Acute Coronary Syndrome Patients After Percutaneous Coronary Intervention in Contemporary Practice: Data from the Multinational, Prospective, Antiplatelet Treatment Outcomes Registry (APTOR)

Value in health, 2011, Vol.14 (7), p.A365-A365

2011

Volltextzugriff (PDF)

PCV11 Treatment and 12-Month Outcomes of Acute Coronary Syndromes Patients Aged < 75 and ≥ 75 Years Undergoing Percutaneous Coronary Intervention: 14-Country Data on 4545 Patients from the Prospective Antiplatelet Treatment Outcomes Registry (APTOR)

Value in health, 2011, Vol.14 (7), p.A366-A366

2011

Volltextzugriff (PDF)

EE263 Impact of Treatment Duration on the Potential Cost-Effectiveness of Disease-Modifying Therapies for the Treatment of Early Symptomatic Alzheimer's Disease

Value in health, 2022-07, Vol.25 (7), p.S385

2022

Volltextzugriff (PDF)

Identifying factors of activities of daily living important for cost and caregiver outcomes in Alzheimer's disease

International psychogeriatrics, 2016-02, Vol.28 (2), p.247-259

2016

Volltextzugriff (PDF)

Cost-effectivenessmodels for Alzheimer's disease and related dementias: IPECAD modelingworkshop cross-comparison challenge

Alzheimer's & dementia, 2023-05, Vol.19 (5), p.1800

2023

Volltextzugriff (PDF)

Determinants of time to institutionalisation and related healthcare and societal costs in a community-based cohort of patients with Alzheimer's disease dementia

The European journal of health economics, 2019-04, Vol.20 (3), p.343-355

2019

Volltextzugriff (PDF)

What Drives Country Differences in Cost of Alzheimer's Disease? An Explanation from Resource Use in the GERAS Study

Journal of Alzheimer's disease, 2017-01, Vol.57 (3), p.797

2017

Volltextzugriff (PDF)

Cost‐effectiveness models for Alzheimer's disease and related dementias: IPECAD modeling workshop cross‐comparison challenge

Alzheimer's & dementia, 2023-05, Vol.19 (5), p.1800-1820

2023

Volltextzugriff (PDF)

1 – 25 von 257

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(233)
Mit Volltextzugriff
(230)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(151)
Life Sciences & Biomedicine
(132)
Humans
(116)
Female
(72)
Male
(72)
Adult
(61)
Neurosciences & Neurology
(60)
Psychiatry
(56)
Schizophrenia
(55)
Neurosciences
(49)
Middle Aged
(39)
Biological And Medical Sciences
(38)
Magnetic Resonance Imaging
(34)
Medical Sciences
(31)
Neuroimaging
(28)
Adolescent
(25)
Medicin Och Hälsovetenskap
(25)
Aged
(24)
Mental Disorders
(24)
Psychology. Psychoanalysis. Psychiatry
(24)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Value In Health
(27)
Schizophrenia Bulletin
(15)
Human Brain Mapping
(11)
Neuroimage
(10)
Schizophrenia Research
(10)
Alzheimer's & Dementia
(8)
Biological Psychiatry
(8)
Crystal Research And Technology
(5)
International Journal Of Clinical Practice
(5)
The Lancet
(5)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Analysis of burden in caregivers of people with Alzheimer’s disease using self-report and supervision hours

Inclusion Of Multiple Studies In Matching Adjusted Indirect Comparisons (Maic)

Utilization of Observational Data as a Proxy Cohort for Comparison Purposes with Open-Label Study Results: An Example from Alzheimer’s Disease

Dependence Levels as Interim Clinical Milestones Along the Continuum of Alzheimer's Disease: 18-Month Results from the GERAS Observational Study

How to deal with missing longitudinal data in cost of illness models in alzheimer’s disease – suggestions from the geras study results

What Factors Predict the Decision to Treat Acute Coronary Syndrome Invasively? Evidence from Clinical Practice

Analysis of factors that affect outcome of primary cadaveric renal transplantation in the UK

Analysis of burden in caregivers of people with Alzheimer's disease using self-report and supervision hours

Factors associated with long-term impact on informal caregivers during Alzheimer's disease dementia progression: 36-month results from GERAS

MSR56 Evaluating the Impact of Using Different Risk Equations for Cost-Effectiveness Evaluation in the US Setting

Determinants of societal costs in Alzheimer's disease: GERAS study baseline results

PCR59 Assessing the Utility Associated with Caregiving in Alzheimer's Disease (AD) with Mild Cognitive Impairment (MCI) and AD Dementia in Japan

PCR24 The Impact of Informal Caregiving in Alzheimer’s Disease Dementia: A Health Utility Study in the UK

Health-related quality of life in people with predementia Alzheimer's disease, mild cognitive impairment or dementia measured with preference-based instruments: a systematic literature review

The GERAS Study: a prospective observational study of costs and resource use in community dwellers with Alzheimer's disease in three European countries--study design and baseline findings

CO19 Sintilimab Plus Chemotherapy for First-Line Treatment of Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer (AMNSQNSCLC): A Systematic Literature Review (SLR) and Network Meta-Analysis (NMA)

Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study

PCV9 Optimal Treatment Shortfalls and Worse 12-Month Outcomes for Diabetic Acute Coronary Syndrome Patients After Percutaneous Coronary Intervention in Contemporary Practice: Data from the Multinational, Prospective, Antiplatelet Treatment Outcomes Registry (APTOR)

PCV11 Treatment and 12-Month Outcomes of Acute Coronary Syndromes Patients Aged < 75 and ≥ 75 Years Undergoing Percutaneous Coronary Intervention: 14-Country Data on 4545 Patients from the Prospective Antiplatelet Treatment Outcomes Registry (APTOR)

EE263 Impact of Treatment Duration on the Potential Cost-Effectiveness of Disease-Modifying Therapies for the Treatment of Early Symptomatic Alzheimer's Disease

Identifying factors of activities of daily living important for cost and caregiver outcomes in Alzheimer's disease

Cost-effectivenessmodels for Alzheimer's disease and related dementias: IPECAD modelingworkshop cross-comparison challenge

Determinants of time to institutionalisation and related healthcare and societal costs in a community-based cohort of patients with Alzheimer's disease dementia

What Drives Country Differences in Cost of Alzheimer's Disease? An Explanation from Resource Use in the GERAS Study

Cost‐effectiveness models for Alzheimer's disease and related dementias: IPECAD modeling workshop cross‐comparison challenge

Suchergebnisse filtern